<p>Inventiva S.A. 赞助的 ADR (NASDAQ:IVA - 获取免费报告) 的股票在周二交易中表现出强劲的交易量。交易期间共成交 1,311,257 股，较前一交易日的 457,841 股增加了 186%。该股票最后交易价格为 $5.5150，之前收盘价为 $5.01。</p>
<h2>分析师评级调整</h2>
<p>多家券商最近对 IVA 发布了报告。Weiss Ratings 在 1 月 22 日的研究报告中重申了对 Inventiva 的 &#34;卖出 (d-)&#34; 评级。瑞银集团在 1 月 7 日的报告中开始覆盖 Inventiva，给予 &#34;买入&#34; 评级和 $12.00 的目标价。Leerink Partners 在 1 月 12 日的研究报告中开始覆盖 Inventiva，给予 &#34;跑赢大盘&#34; 评级和 $12.00 的目标价。巴克莱在 1 月 27 日的研究报告中开始覆盖 Inventiva，给予 &#34;增持&#34; 评级和 $18.00 的目标价。最后，HC Wainwright 在 1 月 28 日的研究报告中对 Inventiva 设定了 $24.00 的目标价，并给予公司 &#34;买入&#34; 评级。三位分析师对该股票给予了强烈买入评级，六位给予了买入评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 &#34;买入&#34;，共识目标价为 $16.56。</p>
<p><strong>获取我们最新的 IVA 股票分析</strong></p>
<h2>Inventiva 价格表现</h2>
<p>该股票的 50 日移动平均线为 $6.03，200 日移动平均线为 $5.36。</p>
<p>Inventiva (NASDAQ:IVA - 获取免费报告) 最近于 2 月 15 日发布了其财报。公司报告本季度每股收益为 ($0.16)。该季度的收入为 $0.01 万美元。分析师平均预计 Inventiva S.A. 赞助的 ADR 本财年的每股收益将为 -2.08。</p>
<h2>对 Inventiva 的对冲基金看法</h2>
<p>机构投资者和对冲基金最近增加或减少了对该股票的持股。Paradigm Biocapital Advisors LP 在第四季度收购了 Inventiva 的新头寸，价值 $18,600,000。ADAR1 Capital Management LLC 在第四季度收购了 Inventiva 的新头寸，价值约 $12,601,000。瑞银集团 AG 在第四季度将其在 Inventiva 的持股增加了 28,881.6%。瑞银集团 AG 目前拥有 2,643,702 股该公司股票，价值 $12,293,000，此前在上一季度购买了额外的 2,634,580 股。SymBiosis Capital Partners LLC 在第四季度收购了 Inventiva 的新股份，价值约 $12,090,000。最后，Millennium Management LLC 在第四季度将其在 Inventiva 的持股增加了 2,267.7%。Millennium Management LLC 目前拥有 2,652,570 股该公司股票，价值 $12,334,000，此前在上一季度购买了额外的 2,540,540 股。机构投资者持有该公司 19.06% 的股票。</p>
<h2>关于 Inventiva</h2>
<p>(获取免费报告)</p>
<p>Inventiva NASDAQ: IVA 是一家临床阶段的生物制药公司，专注于小分子疗法的发现、开发和商业化，以治疗代谢、炎症和纤维化疾病。公司的核心专长在于调节核受体和信号通路，这些受体和通路调控纤维化、炎症和代谢功能障碍。Inventiva 的科学平台整合了药物化学、体外和体内药理学以及转化科学，以推进多样化的治疗候选药物管线。</p>
<p>公司的主要资产，lanifibranor (IVA337)，是一种在开发阶段的全 PPAR 激动剂，针对非酒精性脂肪性肝炎 (NASH)，并在临床前和临床研究中显示出抗炎和抗纤维化效果。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票比 Inventiva 更好</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 $1,000 在 Inventiva 吗？</h2>
<p>在你考虑 Inventiva 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买... 而 Inventiva 并不在名单上。</p>
<p>虽然 Inventiva 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

<p>Inventiva (NASDAQ:IVA) 的交易量显著增加，交易了 1,311,257 股，比前一交易日上涨了 186%。股价从 $5.01 上涨至 $5.5150。分析师的评级意见不一，Weiss Ratings 给出了 “卖出” 评级，而 UBS 等机构则将目标价设定在 $12.00 到 $24.00 之间。机构投资者持有该股票的 19.06%。该公司专注于开发代谢和炎症疾病的治疗方案。尽管目前的评级为 “买入”，但一些分析师建议有更好的投资选择</p>

<p>Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) shares saw strong trading volume on Tuesday . 1,311,257 shares changed hands during trading, an increase of 186% from the previous session's volume of 457,841 shares.The stock last traded at $5.5150 and had previously closed at $5.01.</p>
<div class="lb-trans"><p>Inventiva S.A. 赞助的 ADR (NASDAQ:IVA - 获取免费报告) 的股票在周二交易中表现出强劲的交易量。交易期间共成交 1,311,257 股，较前一交易日的 457,841 股增加了 186%。该股票最后交易价格为 $5.5150，之前收盘价为 $5.01。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级调整</h2>
</div><p>A number of brokerages have recently issued reports on IVA. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Inventiva in a research note on Thursday, January 22nd. UBS Group assumed coverage on Inventiva in a report on Wednesday, January 7th. They set a &#34;buy&#34; rating and a $12.00 price target for the company. Leerink Partners started coverage on Inventiva in a research report on Monday, January 12th. They set an &#34;outperform&#34; rating and a $12.00 price target on the stock. Barclays began coverage on Inventiva in a research note on Tuesday, January 27th. They issued an &#34;overweight&#34; rating and a $18.00 price objective on the stock. Finally, HC Wainwright set a $24.00 target price on Inventiva and gave the company a &#34;buy&#34; rating in a research report on Wednesday, January 28th. Three analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of &#34;Buy&#34; and a consensus price target of $16.56.</p>
<div class="lb-trans"><p>多家券商最近对 IVA 发布了报告。Weiss Ratings 在 1 月 22 日的研究报告中重申了对 Inventiva 的 &#34;卖出 (d-)&#34; 评级。瑞银集团在 1 月 7 日的报告中开始覆盖 Inventiva，给予 &#34;买入&#34; 评级和 $12.00 的目标价。Leerink Partners 在 1 月 12 日的研究报告中开始覆盖 Inventiva，给予 &#34;跑赢大盘&#34; 评级和 $12.00 的目标价。巴克莱在 1 月 27 日的研究报告中开始覆盖 Inventiva，给予 &#34;增持&#34; 评级和 $18.00 的目标价。最后，HC Wainwright 在 1 月 28 日的研究报告中对 Inventiva 设定了 $24.00 的目标价，并给予公司 &#34;买入&#34; 评级。三位分析师对该股票给予了强烈买入评级，六位给予了买入评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 &#34;买入&#34;，共识目标价为 $16.56。</p>
</div><p><strong>Get Our Latest Stock Analysis on IVA</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 IVA 股票分析</strong></p>
</div><h2>Inventiva Price Performance</h2>
<div class="lb-trans"><h2>Inventiva 价格表现</h2>
</div><p>The stock has a 50-day moving average of $6.03 and a 200 day moving average of $5.36.</p>
<div class="lb-trans"><p>该股票的 50 日移动平均线为 $6.03，200 日移动平均线为 $5.36。</p>
</div><p>Inventiva (NASDAQ:IVA - Get Free Report) last released its earnings results on Sunday, February 15th. The company reported ($0.16) EPS for the quarter. The business had revenue of $0.01 million for the quarter. On average, analysts expect that Inventiva S.A. Sponsored ADR will post -2.08 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Inventiva (NASDAQ:IVA - 获取免费报告) 最近于 2 月 15 日发布了其财报。公司报告本季度每股收益为 ($0.16)。该季度的收入为 $0.01 万美元。分析师平均预计 Inventiva S.A. 赞助的 ADR 本财年的每股收益将为 -2.08。</p>
</div><h2>Hedge Funds Weigh In On Inventiva</h2>
<div class="lb-trans"><h2>对 Inventiva 的对冲基金看法</h2>
</div><p>Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Paradigm Biocapital Advisors LP acquired a new position in shares of Inventiva during the fourth quarter worth $18,600,000. ADAR1 Capital Management LLC acquired a new position in Inventiva in the 4th quarter worth about $12,601,000. UBS Group AG boosted its stake in shares of Inventiva by 28,881.6% during the fourth quarter. UBS Group AG now owns 2,643,702 shares of the company's stock valued at $12,293,000 after purchasing an additional 2,634,580 shares in the last quarter. SymBiosis Capital Partners LLC acquired a new stake in shares of Inventiva during the fourth quarter valued at about $12,090,000. Finally, Millennium Management LLC raised its holdings in Inventiva by 2,267.7% in the 4th quarter. Millennium Management LLC now owns 2,652,570 shares of the company's stock valued at $12,334,000 after buying an additional 2,540,540 shares during the last quarter. Institutional investors own 19.06% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近增加或减少了对该股票的持股。Paradigm Biocapital Advisors LP 在第四季度收购了 Inventiva 的新头寸，价值 $18,600,000。ADAR1 Capital Management LLC 在第四季度收购了 Inventiva 的新头寸，价值约 $12,601,000。瑞银集团 AG 在第四季度将其在 Inventiva 的持股增加了 28,881.6%。瑞银集团 AG 目前拥有 2,643,702 股该公司股票，价值 $12,293,000，此前在上一季度购买了额外的 2,634,580 股。SymBiosis Capital Partners LLC 在第四季度收购了 Inventiva 的新股份，价值约 $12,090,000。最后，Millennium Management LLC 在第四季度将其在 Inventiva 的持股增加了 2,267.7%。Millennium Management LLC 目前拥有 2,652,570 股该公司股票，价值 $12,334,000，此前在上一季度购买了额外的 2,540,540 股。机构投资者持有该公司 19.06% 的股票。</p>
</div><h2>About Inventiva</h2>
<div class="lb-trans"><h2>关于 Inventiva</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Inventiva NASDAQ: IVA is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company's core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva's scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.</p>
<div class="lb-trans"><p>Inventiva NASDAQ: IVA 是一家临床阶段的生物制药公司，专注于小分子疗法的发现、开发和商业化，以治疗代谢、炎症和纤维化疾病。公司的核心专长在于调节核受体和信号通路，这些受体和通路调控纤维化、炎症和代谢功能障碍。Inventiva 的科学平台整合了药物化学、体外和体内药理学以及转化科学，以推进多样化的治疗候选药物管线。</p>
</div><p>The company's lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.</p>
<div class="lb-trans"><p>公司的主要资产，lanifibranor (IVA337)，是一种在开发阶段的全 PPAR 激动剂，针对非酒精性脂肪性肝炎 (NASH)，并在临床前和临床研究中显示出抗炎和抗纤维化效果。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Inventiva</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Inventiva 更好</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Inventiva Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Inventiva 吗？</h2>
</div><p>Before you consider Inventiva, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Inventiva 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inventiva wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买... 而 Inventiva 并不在名单上。</p>
</div><p>While Inventiva currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Inventiva 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Inventiva（NASDAQ:IVA）交易量异常高 - 仍然是买入的好时机吗？